Miami, Florida, USA
6th Edition of Neurology World Conference 2026
Speakers - NWC 2026
Sonalika Behera
- Designation: Assistant Professor, Scb Medical College
- Country: India
- Title: Safety and Efficacy of Rituximab In Mogad Five Year Study
Abstract
Objective : To asses the safety & efficacy of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD).
Methodology : This was an 5 years ambispective study carried out on thirty seven patients in a hospital of eastern India from 2019-2024. The primary outcomes were annualized relapse rate & EDSS.
Result : Out of 37 patients ,24 were males , 13 were females. Median disease duration pre RTX was 18.1 months & post RTX was 31.4 months. Median age of onset of disease was 36.4 year(26.9-45.9). Mean EDSS decreased from 5.18 at entry of inclusion to study to 4.43 at 6 months & to 3.81 at 12 months with p value <0.05. ARR has been decreased from 1.2+- 1.3 to 0.5+-0.8 with p value 0.016. Number of relapses were also significantly decreased. Only 1 patient had UTI rest did not have any adverse effect.
Conclusion : Rituximab found to be safe & effective in Indian MOGAD patients.
Neurology World Conference (NWC 2026): Promotes the talks in Advancing the Brain ...
Read More>>
